UNIGE document Scientific Article
previous document  unige:112251  next document
add to browser collection

Association des analogues du GLP-1 et des inhibiteurs du SGLT2 : de nouvelles perspectives ?

Ritz, Claire
Published in Revue médicale suisse. 2017, vol. 13, no. 565, p. 1134-1139
Abstract Type 2 diabetes therapy has expanded considerably over the last decade. Two anti-diabetic therapeutic groups, which are GLP-1 (glucagon-like peptide-1) receptor agonists and SGLT2 inhibitors (sodium-glucose co-transporter-2), have shown efficacy not only on glycemic control but also on weight and other parameters that will be detailed in this article. Cardiovascular safety studies for two of these molecules were shown for the first time to decrease overall and cardiovascular mortality. The combination of these two therapeutic classes provides a logical solution due to their different mechanisms of action. The DURATION-8 study designed to demonstrate the benefits of this combination will also be discussed in this article.
Keywords Blood Glucose/drug effectsCardiovascular Diseases/etiology/prevention & controlDiabetes MellitusType 2/complications/drug therapyDrug TherapyCombinationGlucagon-Like Peptide-1 Receptor/agonistsHumansHypoglycemic Agents/administration & dosage/pharmacology/therapeutic useSodium-Glucose Transporter 2/antagonists & inhibitors
PMID: 28639755
Full text
Article (Published version) (238 Kb) - document accessible for UNIGE members only Limited access to UNIGE
Research group Diabète et régulation des gènes (36)
(ISO format)
RITZ, Claire, JAAFAR, Jaafar, PHILIPPE, Jacques. Association des analogues du GLP-1 et des inhibiteurs du SGLT2 : de nouvelles perspectives ?. In: Revue médicale suisse, 2017, vol. 13, n° 565, p. 1134-1139. https://archive-ouverte.unige.ch/unige:112251

30 hits

0 download


Deposited on : 2018-12-12

Export document
Format :
Citation style :